Business
The Opthea (ASX:OPT) share price up after receiving FDA approval
The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.
Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market.
Another milestone for the Opthea share price
An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the…
-
Business24 hours agoThe ultimate Australian stocks to buy and hold for 10+ years
-
Noosa News19 hours agoLNP Premier David Crisafulli announces ‘Queensland’s royal commission’ into CFMEU
-
Noosa News20 hours agoSouthern NSW farmers call for financial relief as ongoing drought takes a toll
-
Noosa News19 hours agoMan stabbed in physical altercation on the Sunshine Coast